- Datum10.06.2026
- Uhrzeit12:00 - 13:00 Uhr
- Veranstalter
stock3
Taysha Gene Therapies Inc. Registered Shares DL -,00001 Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,85 %
Intraday
6,92 %
1 Woche
-7,27 %
1 Monat
6,73 %
Seit Jahresbeginn
116,61 %
1 Jahr
739,89 %
3 Jahre
-73,91 %
5 Jahre
Passender Service zu Taysha Gene Therapies Inc. Registered Shares DL -,00001
Webinar zu Taysha Gene Therapies Inc. Registered Shares DL -,00001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,250-7,300
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Taysha Gene Therapies Inc. Registered Shares DL -,00001
Keine Dividenden verfügbar
Termine von Taysha Gene Therapies Inc. Registered Shares DL -,00001
Keine aktuellen Termine
Beschreibung
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
